Allopregnanolone potentiates a GABA-withdrawal syndrome in the rat cerebral cortex

Simple item page
dc.contributor.affiliationlnstituto de Fisiología Celular, Departamento de Neurociencias, Universidad Nacional Autónoma de México, Apdo. Postal 70-253, México, 04510 D.F., Mexicoes_ES
dc.contributor.emailsbrailow@ifcsunI.ifisiol.unam.mxes_ES
dc.creatorCalixto, Eduardo
dc.creatorMontiel, Teresa
dc.creatorLemini, Cristina
dc.creatorBrailowsky, Simon
dc.creator.identificadorhttp://orcid.org/0000-0001-9902-9070>Calixto, Eduardoes_ES
dc.date.accessioned2017-06-29T03:41:18Z
dc.date.accessioned2026-03-27T14:33:07Z
dc.date.available2017-06-29T03:41:18Z
dc.date.issued1995es_ES
dc.date.published1995es_ES
dc.description.abstractotrodiomaWe have studied the neuromodulatory effect of the neurosteroid 3a-hydroxy-5a-pregnan-20-one (allopregnanolone-3a-5aP-) in the GABA-withdrawal syndrome (GWS). This is a model of partial epilepsy consisting of an enduring paroxysmal activity recorded at the site of GABA infusion that depends, for its induction, on GABA receptor activation. Rats were chronically implanted for frontal and occipital EEG recording with infusion cannulae fixed on the somatomotor cortical region. When the neurosteroid was infused after or concurrently with GABA, a potentiation of the GWS (i.e. shorter latency and prolonged duration) was observed. No modifications in EEG activity were detected when allopregnanolone was administered alone or prior to GABA administration. These results indicate a neuromodulatory effect of a:Llopregnanolone, dependent on the presence of GABA at the receptor site.es_ES
dc.description.monthAgoes_ES
dc.identifier2528es_ES
dc.identifier.citationMercedes Simoni Nieveses_ES
dc.identifier.eissn1872-7972es_ES
dc.identifier.issn0304-3940es_ES
dc.identifier.numero2es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.paginacion73-76es_ES
dc.identifier.placeIrlandaes_ES
dc.identifier.urihttps://doi.org/10.1016/0304-3940(95)11747-Kes_ES
dc.identifier.urihttps://repositorio.inprf.gob.mx/handle/123456789/4377
dc.identifier.volumen195es_ES
dc.language.isoenges_ES
dc.relation195(2) 73-76p.es_ES
dc.relationversión del editores_ES
dc.relation.jnabreviadoNEUROSCI LETTes_ES
dc.relation.journalNeuroscience letterses_ES
dc.rightsacceso cerradoes_ES
dc.subject.koEpilepsyes_ES
dc.subject.koEEGes_ES
dc.subject.koPlasticityes_ES
dc.subject.koGABA receptores_ES
dc.subject.koAllosteric modulationes_ES
dc.subject.meshAnimalses_ES
dc.subject.meshAnti-Anxiety Agents/pharmacologyes_ES
dc.subject.meshCerebral Cortex/drug effectses_ES
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshDrug Synergismes_ES
dc.subject.meshElectroencephalographyes_ES
dc.subject.meshEpilepsies, Partial/chemically inducedes_ES
dc.subject.meshMalees_ES
dc.subject.meshNeurons/drug effectses_ES
dc.subject.meshPregnanolone/pharmacologyes_ES
dc.subject.meshRatses_ES
dc.subject.meshRats, Wistares_ES
dc.subject.meshSubstance Withdrawal Syndromees_ES
dc.subject.meshgamma-Aminobutyric Acid/adverse effectses_ES
dc.titleAllopregnanolone potentiates a GABA-withdrawal syndrome in the rat cerebral cortexes_ES
dc.typeartículoes_ES

Files

Collections

Artículos de revista